智通财经网·2026-02-06 08:59Group 1 - The core viewpoint of the report is that Fosun Pharma (02196) is expected to achieve net profits of 3.32 billion yuan, 4.68 billion yuan, and 4.77 billion yuan from 2025 to 2027, with year-over-year growth rates of +19.9%, +40.8%, and +2.1% respectively, indicating a positive long-term outlook and a "buy" rating maintained by Yuanta Securities [1] - The company’s subsidiary, Fuhong Hanlin, has granted Eisai the rights for the development, production, and commercialization of the PD-1 monoclonal antibody, Surulitinib, in Japan, with a total upfront payment and milestone payments potentially reaching up to $155.01 million [1] - The upfront payment includes $75 million and up to $80.01 million in regulatory milestone payments, along with potential sales milestone payments of up to $23.33 million based on annual net sales in Japan [1] Group 2 - Surulitinib, a PD-1 monoclonal antibody developed by the company, was launched in China in March 2022 and is expected to generate revenue of 1.31 billion yuan in 2024, reflecting a year-over-year growth of +17.2% [2] - The product has received EU approval for first-line treatment of SCLC in February 2025, making it the first PD-1 monoclonal antibody approved in the EU for this indication, and has also been approved in several other countries, enhancing its international market presence [2] - The company is actively expanding into new markets and indications, with ongoing clinical trials for Surulitinib in various cancers and a new application for gastric cancer treatment expected to be accepted by the Chinese regulatory authority by December 2025 [3]